glutathione withdrawal symptoms Medication Tapering and FDA highlights concerns with using
Description
Cells were lysed as previously described (Mukanganyama et al., 2002)
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis
While the concern is worth observing, it does not seem to be scientifically proven
References Coskun, T., Urva, S., Roell, W.C., Qu, H., Loghin, C., Kirchner, T., et al
